Martin Cannon

Martin Cannon, Ph.D., is a Professor in the Department of Microbiology and Immunology at the University of Arkansas for Medical Sciences (UAMS) College of Medicine. His research focuses on viral and tumor immunology, particularly dendritic cell vaccination strategies for ovarian cancer. He leads clinical trials evaluating Th17-inducing dendritic cell vaccines and collaborates with institutions like MD Anderson Cancer Center and the Mayo Clinic to enhance immunotherapy efficacy.

Education: Ph.D. from the University of London, followed by postdoctoral training at the MRC National Institute for Medical Research (London) and the Scripps Research Institute (La Jolla). Research emphasizes redirecting immune responses to combat ovarian cancer via Th1/Th17 immunity, with findings linking Th17 infiltration to improved patient outcomes. A completed Phase I trial demonstrated recurrence-free survival benefits in ovarian cancer patients.

His work addresses immune suppression in tumor microenvironments and combines dendritic cell therapies with strategies targeting myeloid cell-mediated suppression. Dr. Cannon’s publications span mechanisms of immunosuppression, microbiome impacts on tumors, and clinical advancements in immunotherapy.